Compounds which affect mRNA stability and uses therefor
AssigneeNovation Pharmaceuticals Inc.
InventorsTania Kastelic, Dominique Cheneval, Stephan Ruetz
Life of this patent
Estimating the term…
Abstract
Compounds which induce degradation of mRNA which contains one or more mRNA instability sequences are provided for use as pharmaceuticals, e.g. for use in the prophylaxis or treatment of diseases and medical conditions in general having an etiology associated with the increased or prolonged stability of mRNAs which contain one or more mRNA instability sequences, and which on prolonged or inappropriate expression typically give rise to undesirable effects, e.g. cancer cell growth or an unwanted inflammatory response.
Claims7
A method for the prophylaxis or treatment of a disease or medical condition having an etiology associated with the increased stability of mRNA which contains one or more mRNA instability sequences, comprising administering to a human or animal patient an effective amount of a compound of Formula II:
- wherein
- R1 is H, OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is —CHR7—CHR8— or cis or trans —CR7═CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8— or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof, wherein said compound induces degradation of the mRNA, provided that the disease or medical condition is not one with an etiology associated with or comprising excessive cytokine release.
A method for inducing degradation of mRNA in a human or animal patient, which comprises administering to said patient an effective amount of a compound of Formula II:
- wherein
- R1 is H, OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is -CHR7—CHR8— or cis or trans —CR7═CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8— or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof, wherein said compound induces mRNA degradation in the patient, and wherein the mRNA contains an mRNA instability sequence, provided that the mRNA is not mRNA coding for IL-1β, IL-6 or TNF-α.
A method for the prophylaxis or treatment of a cancer or malignant disease in a human or animal patient comprising administering to the patient an effective amount of a compound of Formula II:
- wherein
- R1 is OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is —CHR7—CHR8— or cis or trans —CR7═CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8— or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof.
A method for the treatment or prevention of oncogene mediated cancers or malignant diseases in a human or animal patient comprising administering to the patient an effective amount of a compound of Formula II:
- wherein
- R1 is OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is —CHR7—CHR8— or cis or trans —CR7=CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8 — or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof.
A method for the treatment or prevention of tumor growth or metastasis in a human or animal patient comprising administering to the patient an effective amount of a compound of Formula II:
- wherein
- R1 is OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is —CHR7—CHR8— or cis or trans —CR7═CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8— or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof.
A method to prevent or reverse multidrug resistance in a tumor cell in a human or animal patient comprising administering to the patient an effective amount of a compound of Formula II:
- wherein
- R1 is OH, halogen, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R2 is OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- R3 is H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—;
- —a—b— is —CHR7—CHR8— or cis or trans —CR7═CR8—;
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, or
- —a—b— is —CHR7—CHR8— and R7 and R8 together with O form an epoxide bridge;
- c is >CH—OH, >C═O or >CH2;
- —d—e— is —CHR7—CHR8— or cis or trans —CR7═CR8—,
- wherein R7 and R8 are the same or different and are H, OH, C1-C4 lower alkoxy, or C1-C4 lower alkyl-COO—, and
- —f—g— is —CH2—CH2—, or cis or trans —CH═CH—,
- or a pharmaceutically acceptable salt thereof or a physiologically-hydrolysable and -acceptable ester thereof.
Dependencies are inferred from the claim text.